Literature DB >> 28523462

Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients.

Soubra Lama1, Domiati Souraya2, Fattouh Youssef3.   

Abstract

Background Current guidelines recommend a low-density lipoprotein cholesterol goal of <1.8 mmol/L (<70 mg/dL) and a non high-density lipoprotein cholesterol (non-HDL-C) goal of <2.6 mmol/L (<00 mg/dL) for coronary artery disease (CAD) patients. Objective This study aimed to describe real-life statin prescription strategies and to assess their effectiveness in terms of LDL-C and non-HDL-C goals attainment in a cohort of CAD patients. Setting Outpatient cardiology specialty clinics located in main Lebanese cities. Methods This is a retrospective crosssectional study. Eligible patients were those who had established CAD, treated with statins and having complete follow-up lipid panel at least 3 months from statin prescription. The following statin prescription strategies were considered in data analysis: prescription of different intensity statin as monotherapy, prescription of a statin in combination with: a low fat diet, another lipid-altering agent and another lipidaltering agent plus a low fat diet. Main outcome measure LDL-C goal attainment for each of the statin prescription strategy. Results Of the 423 CAD statin-treated patients, only 38.5 and 36.6% attained their recommended LDL-C and non-HDL-C goals, respectively. Using a statin in combination with ezetimibe or with another lipid-altering agent plus a low fat diet were significantly associated with LDL-C and non-HDL-C goals attainment. Conclusion Improvement of statin prescription strategies, such as using regular and scheduled dosage of high-intensity statins and combining statin therapy with ezetimibe, is therefore required when managing patients with CAD.

Entities:  

Keywords:  Guidelines; Hypercholesterolemia; LDL; Lebanon; Prescribing; Statins

Mesh:

Substances:

Year:  2017        PMID: 28523462     DOI: 10.1007/s11096-017-0483-x

Source DB:  PubMed          Journal:  Int J Clin Pharm


  41 in total

1.  AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.

Authors:  Sidney C Smith; Emelia J Benjamin; Robert O Bonow; Lynne T Braun; Mark A Creager; Barry A Franklin; Raymond J Gibbons; Scott M Grundy; Loren F Hiratzka; Daniel W Jones; Donald M Lloyd-Jones; Margo Minissian; Lori Mosca; Eric D Peterson; Ralph L Sacco; John Spertus; James H Stein; Kathryn A Taubert
Journal:  Circulation       Date:  2011-11-03       Impact factor: 29.690

2.  The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease.

Authors:  Kheng-Thye Ho; Khong-Whee Chin; Kheng-Siang Ng; Evo Alemao; Srinivasan Rajagopalan; Don Yin
Journal:  Am J Cardiovasc Drugs       Date:  2006       Impact factor: 3.571

Review 3.  Understanding patients' perspective of statin therapy: can we design a better approach to the management of dyslipidaemia? A literature review.

Authors:  Ying Jie Chee; Hian Hui Vincent Chan; Ngiap Chuan Tan
Journal:  Singapore Med J       Date:  2014-08       Impact factor: 1.858

4.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Authors:  Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood
Journal:  Eur Heart J       Date:  2011-06-28       Impact factor: 29.983

5.  Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical records.

Authors:  Maria García-Gil; Jordi Blanch; Marc Comas-Cufí; Josep Daunis-i-Estadella; Bonaventura Bolíbar; Ruth Martí; Anna Ponjoan; Lia Alves-Cabratosa; Rafel Ramos
Journal:  J Clin Lipidol       Date:  2015-10-21       Impact factor: 4.766

6.  Effects of continuous and intermittent feeding on biliary lipid outputs in man: application for measurements of intestinal absorption of cholesterol and bile acids.

Authors:  H Y Mok; K von Bergmann; S M Grundy
Journal:  J Lipid Res       Date:  1979-03       Impact factor: 5.922

7.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Authors:  T A Pearson; I Laurora; H Chu; S Kafonek
Journal:  Arch Intern Med       Date:  2000-02-28

8.  Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients.

Authors:  Gregory A Nichols; Carol E Koro
Journal:  Clin Ther       Date:  2007-08       Impact factor: 3.393

9.  Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients.

Authors:  Dean G Karalis; Brett Victor; Lilian Ahedor; Longjian Liu
Journal:  Cholesterol       Date:  2012-07-25

Review 10.  Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk.

Authors:  Naila Goldenberg; Charles Glueck
Journal:  Vasc Health Risk Manag       Date:  2009
View more
  2 in total

1.  Pharmacist-led academic detailing improves statin therapy prescribing for Malaysian patients with type 2 diabetes: Quasi-experimental design.

Authors:  Mohamed Hassan Elnaem; Mohamad Haniki Nik Mohamed; Hasniza Zaman Huri
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

2.  Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings.

Authors:  Mohamed Hassan Elnaem; Mohamad Haniki Nik Mohamed; Hasniza Zaman Huri; Azarisman Shah Mohd Shah
Journal:  Ther Clin Risk Manag       Date:  2019-01-18       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.